Interestingly, these results strongly suggested that FABP4 mRNA expression level could help to identify NAFL patients likely to belong to the group of NASH patients and also to identify a subgroup of NASH patients likely to progress to cirrhosis and/or HCC. The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatohepatitis.